Mammography Screening With Artificial Intelligence (MASAI)

NAActive, not recruitingINTERVENTIONAL
Enrollment

100,000

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

December 7, 2024

Study Completion Date

May 7, 2025

Conditions
Breast Cancer
Interventions
OTHER

AI screening modality

Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.

OTHER

Conventional screening modality

Screen exams will be read by two radiologists without the support of AI.

Trial Locations (1)

20550

Mammography Unit, Unilabs/Skane University Hospital, Malmo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Unilabs

UNKNOWN

collaborator

Norwegian Institute of Public Health

OTHER_GOV

lead

Region Skane

OTHER